Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/01/10 21:07:57」(JST)

wiki en

Iguratimod is an anti-inflammatory drug for the treatment of rheumatoid arthritis.^[1]^[2] It is approved for use in China and Japan, and is sold by Eisai and Toyama Chemical.^[3]^[4] Its mechanism of action involves the suppression of nuclear factor-kappa B (NF-κB).^[5]

References

^ Keiichi Tanaka (2009). "Iguratimod (T-614): A novel disease modifying anti-rheumatic drug". Rheumatology Reports 1 (1).
^ Lu, Liang-jing; Teng, Jia-lin; Bao, Chun-de; Han, Xing-hai; Sun, Ling-yun; Xu, Jiang-hua; Li, Xing-fu; Wu, Hua-xiang (2008). "Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial". Chinese Medical Journal 121 (7): 615–619. PMID 18466681.
^ Joanne Bronson, Murali Dhar, William Ewing, Nils Lonberg. Manoj C. Desai, ed. "To Market, To Market - 2011". Annual Reports in Medicinal Chemistry 47: 499–569. doi:10.1016/b978-0-12-396492-2.00031-x. |chapter= ignored (help)
^ Eisai Co. (June 29, 2012). "Eisai and Toyama Chemical Receive Approval to Market Anti-rheumatic Agent Iguratimod in Japan" (Press release). Retrieved November 15, 2012.
^ Aikawa Y; Yamamoto M; Yamamoto T; Morimoto K; Tanaka K (2002). "An anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPS- and TNF-alpha-stimulated THP-1 cells without interfering with IkappaBalpha degradation". Inflammation research 51 (4): 188–194. doi:10.1007/PL00000291. PMID 12058956.

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.

English Journal

Inhibitory Effect of Anti-rheumatic Drug Iguratimod for Hepatocellular Carcinogenesis by Inhibition of Serum Interleukin-8 Production.

Sakamoto T1, Ishii Y2, Shiba H2, Furukawa K2, Fujiwara Y2, Haruki K2, Iwase R2, Shirai Y2, Yanaga K2.
Anticancer research.Anticancer Res.2016 Jul;36(7):3301-6.
BACKGROUND/AIM: Angiogenesis is a known factor for the development of hepatocellular carcinoma (HCC). The aim of this study was to assess the property of iguratimod, that is an anti-inflammatory drug for rheumatoid arthritis, on anti-angiogenesis and anti-carcinogensis for HCC.MATERIALS AND METHODS:
PMID 27354586

Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-κB and MAPK pathways.

Gan K1, Yang L2, Xu L2, Feng X3, Zhang Q3, Wang F4, Tan W5, Zhang M6.
International immunopharmacology.Int Immunopharmacol.2016 Jun;35:294-300. doi: 10.1016/j.intimp.2016.03.038. Epub 2016 Apr 16.
INTRODUCTION: Iguratimod (T-614) has been confirmed as a highly efficacious and safe novel disease-modifying anti-rheumatic drug (DMARD) for rheumatoid arthritis therapy in China and Japan due to its potent anti-inflammation effect. Here, we investigate the effects of Iguratimod on osteoclast differ
PMID 27085680

[DMARDs (Focusing on iguratimod)].

Ito S.
Nihon rinsho. Japanese journal of clinical medicine.Nihon Rinsho.2016 Jun;74(6):948-54.
Conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) other than methotrexate (MTX: anchor csDMARDs) are effective for single use, reinforcement of MTX, biologics and induction and maintenance of biologics-free condition. Newly developed iguratimod (IGU) does not suppress immunolo
PMID 27311184

Japanese Journal

関節リウマチ患者に対するイグラチモド単剤投与の経験

佐々木毅志,岡邨興一,米本由木夫,金子哲也,高岸憲二
臨床リウマチ 27(2), 100-105, 2015
目的：関節リウマチ（RA）患者に対する新規の合成Disease modifying anti-rheumatic drugs (DMARDs )であるイグラチモド（IGU）の治療効果について検討を行った．対象・方法：当科において2012年９月から2013年４月までに，IGU単剤が投与開始されたRA患者11名（男性5名，女性6名）について，IGU投与開始前から投与後24週までの治療経過について解析し …
NAID 130005090302

In Vitro Inhibition of Cytochrome P450 2C9-mediated Warfarin 7-Hydroxylation by Iguratimod: Possible Mechanism of Iguratimod–Warfarin Interaction

Yamaori Satoshi,Takami Ken,Shiozawa Ayaka,Sakuyama Kanako,Matsuzawa Naoki,Ohmori Shigeru
Biological and Pharmaceutical Bulletin advpub(0), 2015
… Iguratimod is a novel disease-modifying antirheumatic drug. … A blue letter (safety advisory) for drug interaction between iguratimod and warfarin was issued by the Japanese Ministry of Health, Labour, and Welfare in May 2013. … Iguratimod may affect warfarin metabolism catalyzed by cytochrome P450 (CYP). … However, it is not clear whether iguratimod inhibits warfarin oxidation. …
NAID 130004872296

In Vitro Inhibition of CYP2C9-Mediated Warfarin 7-Hydroxylation by Iguratimod:Possible Mechanism of Iguratimod–Warfarin Interaction

Yamaori Satoshi,Takami Ken,Shiozawa Ayaka [他],Sakuyama Kanako,Matsuzawa Naoki,Ohmori Shigeru
Biological and Pharmaceutical Bulletin 38(3), 441-447, 2015
… Iguratimod is a novel disease-modifying antirheumatic drug. … A blue letter (safety advisory) for drug interaction between iguratimod and warfarin was issued by the Ministry of Health, Labour and Welfare of Japan in May 2013. … Iguratimod may affect warfarin metabolism catalyzed by CYP. … However, it is not clear whether iguratimod inhibits warfarin oxidation. …
NAID 130004872267

Related Pictures

Iguratimod - Wikipedia イグラチモドの作用機序 Iguratimod with certificate of Products イグラチモドはNFκBを阻害する Iguratimod，化学对照品(100mg) Signaling Product name:Iguratimod on sale 摘要：4637-24-5,C5H13NO2,119.1649,N

★リンクテーブル★

リンク元

「イグラチモド」

Iguratimod
Systematic (IUPAC) name
	N-(3-Formamido-4-oxo-6-phenoxy-4H-chromen-7-yl)methanesulfonamide
Clinical data
Trade names	Careram; Kolbet
Legal status	?
Identifiers
CAS number	123663-49-0
ATC code	None
PubChem	CID 124246
ChemSpider	110694
Synonyms	T-614
Chemical data
Formula	C17H14N2O6S
Molecular mass	374.368 g/mol
	SMILES O=S(=O)(Nc3c(Oc1ccccc1)cc2c(O/C=C(\C2=O)NC=O)c3)C;
	InChI InChI=1S/C17H14N2O6S/c1-26(22,23)19-13-8-15-12(17(21)14(9-24-15)18-10-20)7-16(13)25-11-5-3-2-4-6-11/h2-10,19H,1H3,(H,18,20); Key:ANMATWQYLIFGOK-UHFFFAOYSA-N ;

　　[★]

英: iguratimod
商: ケアラム、コルベット
関: 他に分類されない代謝性医薬品

[1] Keiichi Tanaka (2009). "Iguratimod (T-614): A novel disease modifying anti-rheumatic drug". Rheumatology Reports 1 (1).

[2] Lu, Liang-jing; Teng, Jia-lin; Bao, Chun-de; Han, Xing-hai; Sun, Ling-yun; Xu, Jiang-hua; Li, Xing-fu; Wu, Hua-xiang (2008). "Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial". Chinese Medical Journal 121 (7): 615–619. PMID 18466681.

[3] Joanne Bronson, Murali Dhar, William Ewing, Nils Lonberg. Manoj C. Desai, ed. "To Market, To Market - 2011". Annual Reports in Medicinal Chemistry 47: 499–569. doi:10.1016/b978-0-12-396492-2.00031-x. |chapter= ignored (help)

[4] Eisai Co. (June 29, 2012). "Eisai and Toyama Chemical Receive Approval to Market Anti-rheumatic Agent Iguratimod in Japan" (Press release). Retrieved November 15, 2012.

[5] Aikawa Y; Yamamoto M; Yamamoto T; Morimoto K; Tanaka K (2002). "An anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPS- and TNF-alpha-stimulated THP-1 cells without interfering with IkappaBalpha degradation". Inflammation research 51 (4): 188–194. doi:10.1007/PL00000291. PMID 12058956.

匿名

検索

案内

案内

iguratimod